Sio Capital Management LLC Increases Stock Position in Aligos Therapeutics, Inc. $ALGS

Sio Capital Management LLC increased its holdings in Aligos Therapeutics, Inc. (NASDAQ:ALGS - Free Report) by 85.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 335,937 shares of the company's stock after buying an additional 155,217 shares during the period. Aligos Therapeutics accounts for 0.9% of Sio Capital Management LLC's investment portfolio, making the stock its 26th biggest position. Sio Capital Management LLC owned approximately 5.50% of Aligos Therapeutics worth $2,422,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Alyeska Investment Group L.P. purchased a new stake in shares of Aligos Therapeutics during the first quarter worth $3,399,000. Woodline Partners LP bought a new stake in shares of Aligos Therapeutics during the 1st quarter valued at $2,602,000. Heights Capital Management Inc. purchased a new stake in Aligos Therapeutics during the 1st quarter worth about $1,992,000. Adage Capital Partners GP L.L.C. lifted its holdings in Aligos Therapeutics by 43.1% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 465,000 shares of the company's stock worth $3,836,000 after purchasing an additional 140,000 shares in the last quarter. Finally, AlphaQuest LLC bought a new position in Aligos Therapeutics in the 1st quarter worth about $130,000. 60.43% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Aligos Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a "buy" rating and set a $50.00 price objective on shares of Aligos Therapeutics in a research note on Friday, September 12th. Finally, Wall Street Zen lowered shares of Aligos Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, November 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $50.00.

Read Our Latest Analysis on ALGS

Aligos Therapeutics Trading Down 2.9%

Shares of ALGS opened at $9.30 on Tuesday. The company has a market cap of $57.20 million, a PE ratio of -0.47 and a beta of 2.74. The stock has a 50-day moving average price of $9.03 and a 200-day moving average price of $8.53. Aligos Therapeutics, Inc. has a 12-month low of $3.76 and a 12-month high of $46.80.

Aligos Therapeutics (NASDAQ:ALGS - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($3.04) earnings per share for the quarter, missing the consensus estimate of ($2.09) by ($0.95). The company had revenue of $0.74 million during the quarter, compared to the consensus estimate of $0.50 million. Aligos Therapeutics had a negative return on equity of 39.35% and a negative net margin of 3,267.65%. As a group, analysts predict that Aligos Therapeutics, Inc. will post -10.36 earnings per share for the current year.

Aligos Therapeutics Profile

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).

Featured Stories

• Five stocks we like better than Aligos Therapeutics
• How to Invest in the Best Canadian Stocks
• Why Bitcoin ETFs Like IBIT May Be Set to Surge in 2026
• 3 Fintech Stocks With Good 2021 Prospects
• Up Over 20% in 2025, These 3 Stocks Are Boosting Buyback Capacity
• The Basics of Support and Resistance
• Congress Beat the Market Again—Here Are the 3 Stocks They Bought

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Aligos Therapeutics Right Now?

Before you consider Aligos Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aligos Therapeutics wasn't on the list.

While Aligos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here